Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
IGC Pharma, Inc. Common Stock
(NY:
IGC
)
0.3734
+0.0084 (+2.30%)
Official Closing Price
Updated: 6:30 PM EDT, Aug 25, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about IGC Pharma, Inc. Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City
Today 9:00 EDT
Via
ACCESS Newswire
IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial
August 19, 2025
Via
ACCESS Newswire
IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1
August 12, 2025
Via
ACCESS Newswire
IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression
August 05, 2025
Via
ACCESS Newswire
IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025
July 23, 2025
Via
ACCESS Newswire
IGC Pharma Reports Third Quarter Fiscal 2025 Results
February 18, 2025
Via
ACCESS Newswire
IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)
February 11, 2025
Via
ACCESS Newswire
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy
January 08, 2025
Via
ACCESSWIRE
IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards
July 21, 2025
Via
ACCESS Newswire
IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection
July 10, 2025
Via
ACCESS Newswire
IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation
June 30, 2025
Via
ACCESS Newswire
IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025
June 27, 2025
Via
ACCESS Newswire
IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon
June 23, 2025
Via
ACCESS Newswire
IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market
May 22, 2025
Via
ACCESS Newswire
IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting
May 12, 2025
Via
ACCESS Newswire
IGC Pharma Welcomes Strategic Investment from Advisors
April 24, 2025
Via
ACCESS Newswire
IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs
April 21, 2025
Via
ACCESS Newswire
IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program
April 08, 2025
Via
ACCESS Newswire
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health
April 01, 2025
Via
ACCESS Newswire
IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances
March 26, 2025
Via
ACCESS Newswire
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences
March 20, 2025
Via
ACCESS Newswire
IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida
March 17, 2025
Via
ACCESS Newswire
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25"
March 12, 2025
Via
ACCESS Newswire
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the “Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results”
March 10, 2025
Via
ACCESS Newswire
IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection
March 04, 2025
Via
ACCESS Newswire
IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market
February 20, 2025
Via
ACCESS Newswire
IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease
January 28, 2025
Via
ACCESS Newswire
IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor
January 21, 2025
Via
ACCESS Newswire
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
January 13, 2025
Via
ACCESSWIRE
IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025
December 19, 2024
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.